CStone Pharmaceuticals
HKEX:2616
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.82
2.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
CStone Pharmaceuticals
CStone Pharmaceuticals
Revenue
CStone Pharmaceuticals
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CStone Pharmaceuticals
HKEX:2616
|
Revenue
¥456.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥7.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥36.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
47%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥2.9B
|
CAGR 3-Years
59%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
CStone Pharmaceuticals
Glance View
Cstone Pharmaceuticals Co. Ltd. engages in the research and development of highly complex biopharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 264 full-time employees. The company went IPO on 2019-02-26. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The firm conducts its businesses mainly in domestic market.
See Also
What is CStone Pharmaceuticals's Revenue?
Revenue
456.5m
CNY
Based on the financial report for Jun 30, 2024, CStone Pharmaceuticals's Revenue amounts to 456.5m CNY.
What is CStone Pharmaceuticals's Revenue growth rate?
Revenue CAGR 3Y
-26%
Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for CStone Pharmaceuticals have been -26% over the past three years .
You don't have any saved screeners yet
